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a b s t r a c t
The formation of new blood vessels has been shown to be fundamental in the repair of many damaged
tissues, and we have recently shown that the adult human periodontal ligament contains multipotent
stem/progenitor cells that are capable of undergoing vasculogenic and angiogenic differentiation
in vitro and ex vivo. Enamel matrix protein (EMP) is a heterogeneous mixture of mainly amelogenin-
derived proteins produced during tooth development and has been reported to be sometimes effective
in stimulating these processes, including in clinical regeneration of the periodontal ligament. However,
the identity of the speciﬁc bioactive component of EMP remains unclear. In the present study we show
that, while the high-molecular-weight Fraction A of enamel matrix derivative (a heat-treated form of
EMP) is unable to stimulate the vasculogenic differentiation of human periodontal ligament cells (HPC)
in vitro, the low-molecular-weight Fraction C signiﬁcantly up-regulates the expression of the endothelial
markers VEGFR2, Tie-1, Tie-2, VE-cadherin and vWF and markedly increases the internalization of low-
density lipoprotein. Furthermore, we also demonstrate, for the ﬁrst time, that the synthetic homolog
of the 45-amino acid tyrosine-rich amelogenin peptide (TRAP) present in Fraction C is likely to be respon-
sible for its vasculogenesis-inducing activity. Moreover, the chemically synthesized TRAP peptide is also
shown here to be capable of up-regulating the angiogenic differentiation of the HPC, based on its marked
stimulation of in vitro cell migration and tubule formation and of blood vessel formation assay in a chick
embryo chorioallantoic membrane model ex vivo. This novel peptide, and modiﬁed derivatives, might
thereby represent a new class of regenerative drug that has the ability to elicit new blood vessel forma-
tion and promote wound healing in vivo.
 2013 The Authors Published by Elsevier Ltd. Open access under CC BY license.
1. Introduction
The formation of new vascular networks from progenitor cells is
considered to be essential for the repair and regeneration of many
types of tissue in vivo, including the periodontal ligament (PDL)
that supports the teeth [1,2]. This tissue is composed primarily of
ﬁbroblasts, osteoblasts and osteoclasts, and has recently been re-
ported to also contain a precursor/stem cell-like population that
can undergo multi-lineage differentiation [3–9]. Thus, in the pres-
ence of the appropriate biological mediators, human periodontal
ligament cells (HPC) have been reported to be capable of forming
new vascular networks that ensure the supply of sufﬁcient blood
for the repair/healing of damaged PDL and the regeneration of
healthy new tissue in vivo [1,2].
The complex process of neovasculogenesis comprises both
vasculogenic and angiogenic differentiation during adult wound
healing as well as in developing microenvironments [1,10]. Both
vasculogenesis, the differentiation of progenitor/stem cells into
endothelial cells [1,10,11], and angiogenesis, the development of
an organized network of tubular structures originating from
endothelial cells (EC) [1,12,10], are regulated in vitro and in vivo
by a number of biological mediators, including vascular endothelial
growth factor (VEGF), platelet-derived growth factor (PDGF), insu-
lin-like growth factor, transforming growth factor-beta (TGF-b),
basic ﬁbroblast growth factor (bFGF) and epidermal growth factor
(EGF) [1,13–17], and also by enamel matrix proteins (EMP) [18–
22].
EMP is a heterogeneous mixture of components consisting
primarily of peptide isoforms derived from the full-length amelo-
genin gene transcript and is secreted during tooth development
[23]. Crude preparations of EMP and a heat-treated preparation de-
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rived from it, enamel matrix derivative (EMD; Institut Strauman),
have been widely used clinically for regenerating periodontal tis-
sues, including PDL, alveolar bone and cementum, a mineralized
tissue found uniquely in the periodontium [13,24–26,54–56,64].
However, a number of clinical studies carried out to evaluate the
effects of these materials on periodontal soft tissue wound healing
have resulted in discrepant conclusions. For example, periodontal
wounds treated topically with EMD exhibited rapid and complete
healing and PDL regeneration, compared with the control sites that
were not treated with EMD which exhibited only partial healing
and PDL regeneration [28]. In contrast, in a different study it was
shown that a test patient group treated with EMD exhibited only
partial PDL regeneration, comparable to the control group that
did not receive EMD [27]. Similarly, discrepancies were also ob-
served in a number of randomized controlled clinical studies and
histological evaluations, as previously noted and discussed in the
reviews by Sculean et al. [65], Giannobile and Somerman [66]
and Venezia et al. [67].
The above studies highlight the variability of responses to EMP/
EMD therapy of periodontal wound sites. The reasons for these
conﬂicting results are not yet understood, possibly because the
range of parameters involved in determining the clinical outcome
is not yet clear. However, there is much evidence that new blood
vessel (BV) formation is likely to be a central and indispensable
feature of periodontal healing and regeneration [27,28,18–22],
and it is thus possible that the effects of EMP/EMD on the estab-
lishment of a sufﬁcient blood supply may be fundamental to the
clinical efﬁcacy of this material.
A number of studies have therefore examined the effects of
EMD on angiogenic differentiation using model systems in tissue
culture. However, these results have been inconclusive, possibly
because some experimental protocols have used freshly isolated
and non-heat-treated EMP while others have used commercially
prepared and heat-treated EMD [19,29,22,18,30,4]. Thus, although
EMP was reported to strongly stimulate migration/chemotaxis and
the formation of a tubular network of human microvascular endo-
thelial cells (HMVEC) in vitro [19,29], both Johnson et al. [19] and
Thoma et al. [30] showed that EMD did not induce HMVEC migra-
tion/chemotaxis in a cell wound healing assay. Since the composi-
tion of EMP and EMD preparations is likely to vary qualitatively as
well as quantitatively, a number of attempts have also been made
to delineate the speciﬁc protein fraction(s) in these preparations
that have angiogenic activity [19,30]. Johnson et al. [19] examined
the effects of EMP fractions on HMVEC angiogenesis in vitro and
observed that both a low- and a high-molecular-weight fraction
of this preparation were able to stimulate chemotaxis and tube
formation, although the latter fraction also contained some low-
molecular-weight peptides. Similarly, Thoma et al. [30] examined
the effects of EMD on a murine angiogenesis model in vivo and also
reported that both a low- (<6 kDa) and a high-molecular-weight
(<15 kDa) fraction of heat-treated EMD exhibited angiogenic activ-
ity. Although speciﬁc components were not identiﬁed, it is notable
that proteins of relatively low molecular weight were again found
to be present in all of the fractions prepared from EMD [30]. Such
studies highlight the possibility that the discrepant effects of EMP
and EMD on angiogenesis in vitro and in vivo might be related to
the use of heterogeneous protein preparations containing multiple
components that have different effects on angiogenesis.
Further studies aimed at identifying the speciﬁc bioactive
components of EMD have separated two subfractions, by indus-
trial-scale protein fractionation methodologies [31]: Fraction C,
comprising <6 kDa peptides (mainly a 5.3 kDa tyrosine-rich amelo-
genin peptide (TRAP)), and Fraction A, containing a mixture of
>6 kDa peptides, including a leucine-rich amelogenin peptide,
sheathlin proteins and the full-length amelogenin protein [31]. In
the present study we therefore examined the effect of EMD and
these Fractions A and C, as well as a chemically synthesized
5.3 kDa TRAP peptide that is the main component of the low-
molecular-weight Fraction C, on HPC, which are capable of under-
going vasculogenic differentiation when cultured in endothelial
medium in vitro [3]. In addition, since we have also previously
shown [3,4] that such cells are able to undergo angiogenic differen-
tiation, forming tubular-like structures with minimal sprouting,
the present study examined the effects of EMD components on
HPC cell angiogenesis in vitro, including chemotaxis and the ability
to form BV-like structures. The chick embryo chorioallantoic mem-
brane (CAM), a highly vascularized extra-embryonic membrane
that serves as a transient gas exchange surface similar to the lungs
[32–34], was also utilized as an ex vivo model for examining the
angiogenic effects of these EMD components.
2. Materials and methods
2.1. Isolation and culture of primary adult HPC and EC
HPC were obtained from the PDL tissues of three individual
donors (three males, aged between 18 and 25 years) and were used
as a source of progenitor/stem cells to investigate the effects of
EMD component(s) on vasculogenesis, as previously described
[3,4]. Patients undergoing routine third molar tooth extractions
signed informed consent, in accordance with the protocol ap-
proved by the Joint Research and Ethics Committee of the Eastman
Dental Institute and Hospital. Brieﬂy, ligament tissue from the
middle portion of the root of the tooth was digested with
3 mg ml1 collagenase type I and 4 mg ml1 dispase (both from
Sigma, Gillingham, UK) for 1 h at 37 C, as previously described
[3,4]. Single-cell suspensions of HPC were obtained by passing
the cells through a stainless steel ﬁlter (70 lm gauge; Falcon, Bec-
ton Dickinson, Cowley, UK) and cultured in growth medium (GM)
comprising a-modiﬁed Eagle’s medium (Gibco Life Technologies
Ltd, Paisley, UK) and 10% fetal calf serum (PAA Laboratories, Yeovil,
UK) supplemented with 200 U ml1 penicillin, 200 lg ml1 strep-
tomycin and 2 mM L-glutamine (all from Gibco) at 37 C in a
humidiﬁed atmosphere of 5% CO2 in air. As noted above, three sep-
arate HPC populations, each obtained from a different donor, were
pooled together and used between passages 3 and 6.
Human umbilical vein endothelial cells (HUVEC; Lonza, Slough,
UK) were used as the positive control/source of EC, as they have
previously been shown to be capable of angiogenic differentiation
[35,19,22]. The HUVEC were used between passages 3 and 6.
2.2. Effects of EMD and the EMD fractions on HPC cell vasculogenic
differentiation
2.2.1. Immunocytochemical evidence of vasculogenesis
HPC were seeded into 24-well plates at a density of 2.5  104 -
cells well1, cultured in GM for 2–3 days and the medium replaced
with endothelial basal medium-2 containing increasing concentra-
tions of EMD components (1–100 lg ml1). EBM-2 supplemented
with the endothelial growth factors (GF) VEGF (150 ng ml1) and
EGF (50 ng ml1) (EBM-2 + GF) (Peprotech, London, UK), a medium
which has previously been shown to induce murine and human
mesenchymal stem cell vasculogenesis in vitro [36,37], was used
to facilitate vasculogenic differentiation, as previously described
[36,37]. The EBM-2, EBM-2 + EMD components and EBM-2 + GF
were changed every 3–4 days. After 5 weeks, immunostaining of
replicate cultures was carried out, as previously described [3,4],
for two markers that are expressed by terminally differentiated/
mature endothelial cells: VE-cadherin, an EC adhesion protein
[3,4,36,37], and von Willebrand factor (vWF), a blood glycoprotein
localized in EC-speciﬁc vesicles [3,4,36,37]. Brieﬂy, cells were ﬁxed
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in 4% paraformaldehyde (Merck, Poole, UK) for 15 min at room tem-
perature (RT) and permeabilized using 0.1% Tritox X-100 (Sigma)
for 15 min at RT. They were then treated with a blocking solution
containing 10% normal goat serum (NGS) in phosphate-buffered
saline (PBS) for 1 h and incubated for 1 h at RT with primary mouse
monoclonal anti-VE-cadherin (Insight Biotechnology, London, UK)
and anti-vWF (Abcam, Cambridge, UK) antibodies diluted 1:100
in PBS containing 1% NGS. Incubation was then carried out with
goat anti-mouse Alexa Fluor secondary antibody (Invitrogen, Pais-
ley, UK) diluted 1:200 in PBS containing 1% NGS for 1 h at RT. VE-
cadherin- and vWF-positive cells were visualized by their green
ﬂuorescent staining. Nuclei were stained blue using Hoechst dye.
The proportions of VE-cadherin- and vWF-positive cells were deter-
mined by manual counting of ﬁve separate ﬁelds of each culture.
Total RNA was extracted from replicate cultures for conven-
tional reverse transcriptase–polymerase chain reaction (RT-PCR)
analysis of the VEGF receptor-1 (VEGFR1) and VEGFR2 (measured
at week 1) genes, involved at an early stage of VEGF-mediated vas-
culogenic differentiation. The Tie-1 and Tie-2 genes, involved in an
angiopoietin-mediated late stage of vasculogenesis, were mea-
sured after 2 weeks, and the VE-cadherin gene, involved in produc-
ing EC adhesion protein at a late stage of vasculogenesis, was
measured at week 3, as described in previously [3,4]. Since mRNA
transcripts are expressed much earlier than the corresponding pro-
teins, the VE-cadherin gene was measured at week 3 and immuno-
staining of VE-cadherin protein was carried out at week 5. Primer
sequences are noted in Supplementary Table 1. To obtain a semi-
quantitative estimate of the relative level of mRNA transcript
expression, the intensity of the cDNA band corresponding to each
PCR product was measured by densitometry using ImageJ (NIH
software) and normalized to that of GAPDH used as an internal
control.
2.2.2. Functional assay of vasculogenic differentiation by ﬂow
cytometry (FCM)
Receptor-mediated endocytosis of acetylated low-density lipo-
protein (LDL), involved in the transport of triglycerides and choles-
terol into the blood, is a key functional indicator of terminal
vasculogenic differentiation [38,57]. To determine whether HPC
exhibited this activity when cultured in differentiation medium
and the effects of EMD component(s), the cells were cultured in
24-well plates in GM for 2–3 days and then the medium was re-
placed with EBM-2 alone, EBM-2 + EMD components (test sample)
and EBM-2 + GF (positive control sample). After 5 weeks, cultures
were washed with PBS and incubated for 2 h with EBM-2 contain-
ing 100 ng ml1 Alexa Fluor-labeled acetylated LDL (Invitrogen,
Paisley, UK), ﬁxed with 4% paraformaldehyde (PFA) for 15 min at
RT and the nuclei stained using Hoechst dye. Concurrently, FCM
was carried out on duplicate cultures to measure the intracellular
levels of Alexa Fluor-labeled acetylated LDL, according to the pro-
cedure described by [8], as follows. The cells were detached from
the culture dish by incubating with trypsin–ethylenediaminetetra-
acetic acid (EDTA) (0.25% trypsin, 1 mM EDTA) (Gibco) for 5 min at
37 C, centrifuged, ﬁxed in 4% PFA and permeabilized using 0.1%
Triton X (Sigma) for 15 min at RT. The cells were then centrifuged
and resuspended in 200 ll of PBS and the ﬂuorescence intensity of
10,000 individual cells measured using a ﬂow cytometer (FACScan;
Becton–Dickinson, Cowley, UK). Data analysis was carried out
using the WinMDI 2.8 software program.
2.3. Effects of EMD components on angiogenesis
2.3.1. Chemotaxis assay
Chemotaxis/migration of endothelial precursors to the wound
site followed by formation of angiogenic structures by the accumu-
lated endothelial precursors is one of the initial events of angio-
genic differentiation in vivo [39,29]. To examine the effect of
EMD components on HPC cell chemotaxis, a two-dimensional cell
‘‘wound healing’’ migration assay was performed, as previously de-
scribed [18,40]. Brieﬂy, 2.5  104 EC well1 were cultured in GM
alone in a 24-well plate for 3–4 days or until conﬂuent, after which
a ‘‘wound’’ was created in vitro by scraping off the cells using a pip-
ette tip (200 ll) in a straight horizontal line (1 mm wound in
width). The cultures were then washed with PBS and recultured
with EBM-2 alone, EBM-2 + EMD components (test samples) and
EBM-2 + GF (positive control samples) for 12 h. For analysis of cell
migration (i.e. ‘‘wound healing activity’’), microscopic images of
the wound were taken immediately after scraping the cells (0 h)
and after 6 and 12 h in the absence and presence of EMD compo-
nents and GF. Cell migration was quantiﬁed by measuring the area
of the wound (in pixel counts) using ImageJ software, using the fol-
lowing equation: area of wound (no cells) at 0 h minus area of
wound at 6 or 12 h in the absence and presence of EMD compo-
nent(s) and GF. Full healing of a monolayer wound is the full clo-
sure of wounded area as a result of cell migration, while no
healing is equivalent to zero (the cell-free wound area is the same
at the 0 h test time period). Replicate experiments were also per-
formed using HUVEC as a positive control.
2.3.2. Angiogenic structure formation in vitro
The formation of angiogenic structures by endothelial precur-
sors in vitro was performed using an angiogenesis assay kit (Mil-
lipore, Billerica, MA, USA), as described in previous reports
[3,34,35,41]. The assay comprises a gel of basement membrane
proteins (laminin, collagen type IV, heparan sulfate proteoglycan,
entactin and nidogen) on which the endothelial precursors are
cultured and align to form polygonal tube-like structures in a
multi-step process involving cell adhesion, migration, growth
and differentiation [34,39,41]. In this assay, 104 HPC were plated
on gel-coated 96-well plates and cultured in the presence of
EBM-2 alone, EBM-2 + EMD components (test samples) and
EBM-2 + GF (positive control sample). After 5 and 15 h, digital
images were obtained using bright-ﬁeld microscopy. For quanti-
tative analysis, branch points of polygonal tube-like structures
in each culture condition were scored in ﬁve random ﬁelds, as de-
scribed by the manufacturer of the kit and other reports [35,22].
Similar experiments were also carried out using HUVEC as a po-
sitive control.
2.4. CAM assay of angiogenesis ex vivo
The assay of the chick embryo CAM, a specialized highly vascu-
lar extra-embryonic tissue formed during avian embryogenesis,
has been widely used to examine angiogenic compounds including
bFGF [42,43], VEGF [44], EGF [45], retinoids [46] and somatostatin
[47], mainly because of its accessibility for monitoring BV forma-
tion over the course of the experiment and relatively rapid out-
come [34,32,33]. It was therefore used in the present study to
determine the effects of EMD components on angiogenesis
ex vivo. Fertilized White Leghorn chick eggs (Joice and Hill Poultry
Ltd, Peterborough, UK) were incubated at 37 C in 70–80% relative
humidity in air for 3.5 days. The eggs were then carefully cracked
open and the developing embryos transferred into 10 cm2 Petri
dishes and recultured. On day 7, UV-sterilized ﬁlter disks
(3 mm2) were placed on the CAM where BV were visible and
15 ll of EMD components containing 1, 25, 50 and 100 lg ml1
(test samples) were added dropwise onto the disks. Replicate eggs
were treated with 15 ll of 100 lg ml1 bovine serum albumin in
cell culture grade water (Thermo Scientiﬁc) as control samples.
The eggs were then reincubated for a further period of 3 days,
and the capillaries that had sprouted from the arteries of the
CAM around the disks were photographed and counted in each
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micrograph, then analyzed using ImageJ software as previously de-
scribed [48,35].
2.5. Statistical analysis
The RT-PCR data are shown as the mean fold-change ± standard
error (SE) of three separate experiments compared with that of
control cells cultured in EBM-2 alone (deﬁned as 1.0). One-way
analysis of variance was used to assess statistically signiﬁcant dif-
ferences (p < 0.05), followed by Bonferroni corrections (p < 0.05)
for multiple comparisons between the means (SPSS 11.0 software,
Chicago, IL).
3. Results
3.1. Vasculogenic differentiation
3.1.1. Effects of increasing concentrations of EMD and the EMD
fractions on vasculogenic differentiation of HPC
Vasculogenic differentiation of progenitor/stem cells into EC is
considered pivotal in new BV formation in embryological develop-
ment and also in adult wound healing [1,10], and this process has
also been reported previously in adult HPC cultured in endothelial
basal medium (EBM-2) for 5 weeks [3]. To examine whether EMD
and the EMD fractions modulate vasculogenesis, the HPC were
incubated in EBM-2 alone and EBM-2 + EMD. The representative
micrographs in Fig. 1 show that only few VE-cadherin immuno-
stained cells were present in cells cultured in EMD alone, whereas
in the presence of Fraction C (30 lg ml1) the VE-cadherin-positive
cells were more evident and the staining was found to be localized
at the lateral borders of the cells (junctions), as previously reported
using endothelial precursors derived from human umbilical cord
[49,50] (Fig. 1). In contrast, in the presence of Fraction A no VE-cad-
herin-positive cells were detected. The results in Table 1 show that
when cultured in EBM-2 alone for 5 weeks, 8.5 ± 1.3% of the HPC
were positive for VE-cadherin, very similar to the proportion of
VE-cadherin-positive cells observed when they were cultured in
EBM-2 in the presence of 1, 3 and 10 lg ml1 EMD (9.2, 9.7 and
10.2% positive cells, respectively). However, in the presence of
higher concentrations of EMD (30 and 100 lg ml1), 13.0 and
15.4% of the HPC were VE-cadherin-positive, signiﬁcantly greater
than the proportion of positive cells when cultured in EBM-2 alone
(8.5%; Table 1). Increasing concentrations of Fraction C also mark-
edly increased the number of VE-cadherin-expressing cells, with
30 lg ml1 resulting in 29.2% positive cells, although the presence
of 100 lg ml1 Fraction C did not further increase the relative pro-
portion of positive cells. It is notable that the proportion of VE-cad-
herin-positive cells in the presence of 30 and 100 lg ml1 Fraction
C was also signiﬁcantly higher than observed in the presence of the
same concentrations of EMD, as shown in Table 1. Further experi-
ments were therefore carried out to establish this apparent ability
of Fraction C to actively promote vasculogenic differentiation by
using a chemically synthesized form of the TRAP peptide, the main
component of Fraction C, while Fraction A was not examined fur-
ther since the results in Table 1 demonstrated that this fraction sig-
niﬁcantly suppressed HPC vasculogenesis.
3.1.2. Effects of TRAP on vasculogenic differentiation
As noted above, TRAP has previously been reported to be a main
component of Fraction C [31], and in the present study this peptide
was obtained by chemical synthesis and its pro-vasculogenic
activity, examined as shown in Fig. 2 and Table 2. In control HPC
cultured in EBM-2 alone, VE-cadherin staining was found to be
localized at the lateral borders (junctions) of the HPC. vWF staining
was observed in diffuse intracellular vesicular structures within
the HPC (possibly comparable to Weibel–Palade-like bodies, char-
acteristically associated with endothelial cells, [49,50]). Similar
cellular localization was observed in the HPC cultured in the
presence of TRAP (Fig. 2), although quantitative assessment of
the effect of the peptide showed that TRAP markedly enhanced
vasculogenic differentiation of the HPC. Thus, as with Fraction C,
the presence of 30 lg ml1 TRAP resulted in 26.2% of the cells
exhibiting VE-cadherin staining after 5 weeks of culture, compara-
ble to the proportion of VE-cadherin-positive cells observed in HPC
cultures containing GF (21.7%) (p < 0.05) used as a positive control
and signiﬁcantly higher than the 8.5% positive cells when cultured
in EBM-2 alone (p < 0.05) (Table 2). Similarly, in the presence of
TRAP, 23.1% of the HPC were found to also express vWF (a late
endothelial cell protein previously localized in Weibel–Palade
vesicles [51]), again comparable to the proportion of cells in the
positive control cultures containing GF (17.4%) (p < 0.05) and sig-
Fig. 1. Effects of increasing concentrations of EMD and the EMD fractions on VE-cadherin immunostaining of HPC. Representative micrographs of VE-cadherin of HPC
cultured for 5 weeks in EBM-2 alone and EBM-2 containing EMD (100 lg ml1), Fraction C (30 lg ml1) and Fraction A (100 lg ml1), then immunostained for VE-cadherin.
The nuclei are stained blue with Hoechst dye. Note the apparently greater numbers of VE-cadherin-positive cells (green ﬂuorescence) following incubation with Fraction C, as
indicated by the white arrows.
Table 1
Effect of increasing concentrations (l-100 lg/ml) of EMD and the EMD Fractions on
VE-cadherin staining of PDL cells cultured for 5 weeks in EBM-2. The numbers are the
% of VE-cadherin-positive cells, as described in the Materials and methods. The values
are the means ±SE of three measurements of three separate experiments.
Conc. (lg/ml) VE-cadherin-positive cells (% of total cells)
EMD Fraction C Fraction A
1 9.2 ± 1.6 9.3 ± 1.9 3.1 ± 1.4*
3 9.7 ± 1.7 15.1 ± 2.2*,§ 2.6 ± 1.7*
10 10.2 ± 1.8 20.7 ± 3.0*,§ l.l ± 0.8*
30 13.0 ± 2.2* 29.2 ± 3.4*,§ 0.0
100 15.4 ± 1.2* 27.4 ± 4.0*,§ 0.0
The control cultures (EBM-2 alone) had 8.5 ± 1.3% VE-cadherin positive cells after
5 weeks.
* Indicates signiﬁcant difference compared with EBM-2 alone (p < 0.05).
§ Indicates signiﬁcantly higher than EMD (p < 0.05).
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niﬁcantly higher than the 7.1% positive cells when cultured in
EBM-2 alone (p < 0.05). These ﬁndings indicate that the TRAP pep-
tide, like Fraction C of EMD, appears to stimulate HPC vasculogenic
differentiation in vitro, comparable to that elicited by the presence
of vasculogenic growth factors.
3.1.3. Effects of TRAP on vasculogenic gene expression
It was shown previously that the expression of a number of
endothelial genes was elevated when HPC were cultured in EBM-
2 alone [3]. Notably, the addition of TRAP was found to further
up-regulate endothelial gene expression by the HPC, as shown in
the representative RT-PCR gels in Fig. 3. Thus the presence of
30 lg ml1 TRAP signiﬁcantly increased the relative level of the
early endothelial gene VEGFR2 mRNA transcript (by 3.9-fold), of
the late Tie-1 and Tie-2 tyrosine kinases essential for angiopoie-
tin-mediated vasculogenesis [11] (by 6.2 and 6.8-fold, respec-
tively) and of the VE-cadherin mRNA (by 2.4-fold). Similar but
less pronounced relative gene expression proﬁles were observed
in the positive control HPC cultures containing GF (Fig. 3). In con-
trast, the relative level of the VEGFR1 gene transcript was unaf-
fected when the cells were cultured in the presence of TRAP and
in the presence of GF, as shown in Fig. 3.
3.1.4. Effects of TRAP on vascular cell functional activity
HPC were also examined for the effects of TRAP on internaliza-
tion of acetylated LDL, a key functional indicator of terminal
vasculogenic differentiation [38], by incubating the cells for
5 weeks in the absence and presence of 30 lg ml1 TRAP (and GF
as a positive control). The results in Fig. 4(i) show that, after 2 h
of incubation with green ﬂuorescent-tagged acetylated LDL,
cultures incubated with TRAP and with GF appeared to contain a
similarly high proportion of ﬂuorescent-labeled cells (i.e. those
that had internalized acetylated LDL), compared with many fewer
positive cells when cultured in GM or EBM-2 alone. Measurement
of the relative levels of green ﬂuorescence using FCM showed that
approximately 72% of the cells internalized acetylated LDL when
cultured with TRAP and nearly 67% when cultured with GF (posi-
tive control), whereas only 26.2% of the cells were positive after
culture in EMB-2 alone (p < 0.05) (Fig. 4(ii)). Thus the presence of
TRAP appears to promote a signiﬁcant increase in acetylated LDL
uptake, similar to that found in the presence of GF, indicating a
marked enhancement of vascular cell activity.
3.2. Angiogenic differentiation in vitro
3.2.1. Effects of TRAP on chemotactic migration to wound sites in vitro
Following vasculogenic differentiation of progenitor/stem cells,
the newly formed endothelial precursors migrate to the wound site
of damaged tissue and develop into an organized network of tubu-
Fig. 2. Effects of TRAP on vasculogenic differentiation of HPC. Representative
micrographs of HPC immunostained for VE-cadherin and vWF after culture in EBM-
2 alone, EBM-2 + TRAP (30 lg ml1) and EBM-2 + GF for 5 weeks. The nuclei are
stained blue with Hoechst dye and the white arrows show the green ﬂuorescence of
VE-cadherin staining at the lateral borders (junctions) of the cells. The white
arrowheads show the punctate green ﬂuorescence staining of vWF. Note apparently
greater numbers of VE-cadherin and vWF-positive cells when cultured in the
presence of TRAP.
Table 2
Effects of TRAP (30 lg/ml) on VE-cadherin and vWF staining of PDL cells cultured for
5 weeks in EBM-2. Cells cultured in EBM-2 + GF was used as a control. The numbers
are the % of VE-cadherin- and vWF-positive cells. The values are the means ± SE of
three measurements of three separate experiments.
Markers VE-cadherin and vWF-positive cells (% of total cells)
EBM-2 alone +TRAP +GF
VE-cadherin 8.5 ± 1.3 26.2 ± 3.7* 21.7 ± 3.1*
vWF 7.1 ± 2.8 23.1 ± 5.6* 17.4 ± 4.7*
* Indicates signiﬁcant difference compared with EBM-2 alone (p < 0.05).
Fig. 3. Effect of TRAP on vasculogenic genes of HPC. (i) A representative RT-PCR gel
showing the expression of the early vasculogenic genes VEGFR1 and VEGFR2 and
the late genes Tie-1, Tie-2 and VE-cadherin by HPC cultured for 3 weeks in EBM-2
alone, EBM-2 + GF and EBM-2 + TRAP. (ii) The values are the changes in PCR product
band intensity relative to GAPDH of cells cultured in the presence of GF and TRAP
compared with EBM-2 alone, deﬁned as 1.0. The values are the means ± SE of
triplicate measurements. ⁄Signiﬁcant difference compared with EBM-2 alone
(p < 0.05). Note the apparent up-regulation of HPC mRNA transcripts of VEGFR2,
Tie 1, Tie 2 and VE-cadherin in the presence of TRAP.
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lar structures leading to the formation of BV in vivo, a deﬁning
feature of angiogenic differentiation [39,1,10,16,29]. In vitro it
has been shown, using a two-dimensional wound healing assay,
that such putative precursors cells can apparently be induced to
migrate to ‘‘wound’’ sites by angiogenic growth factors, including
VEGF and EGF [40,52]. In view of the above results indicating that
TRAP was capable of inducing vasculogenic differentiation, further
studies were carried out to determine whether this peptide also af-
fected angiogenesis, as measured by its effect on HPC chemotaxis
in a two-dimensional in vitro wound healing assay as described
in Materials and methods. The results in Fig. 5 show that HPC
migrated to the wound site during 6 h of exposure to the TRAP
peptide, resulting in full closure of the wound site by 12 h, in con-
trast to cultures maintained in differentiation medium alone,
which showed only partial closure at 12 h. Moreover, the results
in Table 3 show that HPC in control cultures (incubated with
EBM-2 alone) migrated over an area of approximately 22,500 pix-
els after 6 h and 32,986 pixels after 12 h, whereas there was a sig-
niﬁcant increase in the migration of the HPC when they were
cultured with EBM-2 and TRAP for 6 h (58,360 pixels) and for
Fig. 4. Assessment of LDL-uptake by HPC treated with TRAP. Uptake of ﬂuorescent-labeled LDL by HPC cultured in EBM-2 alone, EBM-2 + TRAP and EBM-2 + GF for 5 weeks.
(i) White arrows show the internalization of LDL as visualized by ﬂuorescence microscopy. Cells showing green ﬂuorescent staining show internalized LDL and nuclei of the
cells are stained blue. (ii) Representative FCM histogram of the levels of intracellular ﬂuorescent-labeled LDL. In (ii), the shaded proﬁles show the ﬂuorescence distribution of
the TRAP and GF-treated cells, while the open proﬁle shows the control cells cultured in EBM-2 alone. The vertical lines have been arbitrarily selected at a value of 75
ﬂuorescence units. The events on the left side of the vertical lines are considered as non-ﬂuorescent cells (negative cells) and events on the right side of the vertical line are
considered as ﬂuorescent cells (positive cells). Note the increased proportion of green ﬂuorescent cells in the presence of TRAP and GF, compared with control conditions.
Fig. 5. Determination of the effects of TRAP on HPC chemotaxic activity in a cell wound healing assay. Representative microscopic images of HPC cultured in EBM-2 alone,
EBM-2 + TRAP (30 lg ml1) and EBM-2 + GF for 6 and 12 h following the creation of an in vitro cell wound, as described in Materials and methods. The area between the black
dashed lines shows the size of the wound (space without cells), which was measured in pixels. Magniﬁcation 10. Note the apparent full closure of the cell wound after 12 h
of incubation with TRAP, compared with only partial closure in the presence of EBM-2 alone and GF.
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12 h (67,996 pixels) (p < 0.05). As in cultures containing TRAP,
there was also a marked increase in HPC migration in the positive
control of EBM-2 + GF (49,053 and 53,136 pixels after 6 and 12 h,
respectively, p < 0.05; Table 3). It is notable that similar effects of
TRAP (and GF) on migration to wound sites were observed using
HUVEC as positive control cells (Supplementary Material 1). The
above ﬁndings thus indicate that TRAP induces the initial chemo-
tactic phase of angiogenic differentiation and BV formation, com-
parable to that induced by angiogenic GF.
3.2.2. Effects of TRAP on formation of branched angiogenic-like tubular
structures in vitro
The accumulation of platelets (thrombocytes) at a ﬁbrin clot
in vivo provides a growth-factor-rich environment that attracts
endothelial precursors to migrate to the wound site and induces
their organization into tubular-like structures that ultimately form
BV [53]. In vitro tubule-like structure formation by endothelial pre-
cursors can be demonstrated morphologically when endothelial
precursors are cultured on a gel of basement membrane proteins
in the presence of angiogenic factors [34,35,41]. The present study
therefore examined whether TRAP is also capable of inducing the
formation of branched, tubular angiogenic-like structures, as de-
scribed in Materials and methods. The results in Fig. 6(i) show that
a complex polygonal tubular network, morphologically character-
istic of angiogenic differentiation, was formed when HPC were cul-
tured in EBM-2 in the presence of TRAP for 5 h, whereas relatively
fewer of these structures were present in control cultures of HPC
(in EBM-2 alone), as determined by manual counting of branching
points (described in Materials and methods) of polygonal tubular-
like structures. Thus, in the presence of TRAP there were nearly 110
branch points of such structures, similar to the 82 branch points
observed in the presence of EBM-2 + GF and signiﬁcantly more
than the 22 branch points when the cells were cultured in
EBM-2 alone (p < 0.05; Fig. 6(i)). In addition, HPC cultured for an
extended period of 15 h in the presence of TRAP demonstrated
the formation of distinct elongated BV-like structures (Fig. 6(ii)),
in contrast to HPC cultured with EBM-2 alone in which these struc-
tures were not detected (data not shown). Similar results were
obtained when HUVEC (positive control cells) were cultured on a
basement membrane protein gel in the presence of EBM-2, EBM-
2 + TRAP and EBM-2 + GF (data not shown). These results thus
indicate that TRAP induces the organization of HPC into tubular-
like structures in an in vitro angiogenesis assay, comparable to
the inductive effects of angiogenic GF.
3.3. Effects of TRAP on CAM angiogenesis ex vivo
Since TRAP appears to be capable of stimulating angiogenic
differentiation of HPC and mature EC in vitro, as indicated by the
results presented above, the present study used the CAM model
to examine whether TRAP also exhibited angiogenic activity
ex vivo, as described in Materials and methods. The results in
Fig. 7 show that when 7-day-old chick embryos were treated with
25 and 50 lg ml1 TRAP for 3 days, the disks that had been placed
over the CAM appeared to be surrounded by capillaries that had
sprouted from arteries (Fig. 7). Although 1 lg ml1 TRAP had no
signiﬁcant effect on the appearance of such ‘‘allantoic capillaries’’
(capillaries sprouted from the arteries of the developing CAM of
chick embryo responsible for gas exchange and removal of the
waste products [34,42,43]) compared with the control CAM, the
presence of 25 and 50 lg ml1 TRAP signiﬁcantly increased the
number of capillaries in the CAM (2.6- and 2.8-fold, respectively;
p < 0.05). However, increasing the TRAP concentration to
Table 3
Effects of TRAP on migration of PDL cells when cultured in EBM-2 alone. EBM-2 +
TRAP (30 lg/ml) and EBM-2 + GF for 6 and 12 h after creating the cell wound in vitro.
The numbers are the average (of 3 separate experiments) of the measurement of area
(in pixel counts  103) of PDL migration (area of wound (no cells) at 0 h minus area of
wound at 6 or 12 h in the absence and presence of TRAP and GF).
Conditions Cell migration (in pixels  103)
6 h 12 h
EBM-2 alone 22.5 ± 0.37 33.0 ± 2.16
+TRAP 58.3 ± 1.19* 68.0 ± 1.47*
+GF 49.0 ± 2.10* 53.1 ± 2.24*
* Indicates signiﬁcant difference compared with EBM-2 alone (p < 0.05).
Fig. 6. Angiogenic structure formation by HPC in vitro. (i) HPC cultured for 5 h in EBM-2 alone, EBM-2 + TRAP (30 lg ml1) and EBM-2 + GF. The numbers are the angiogenic
structure branching points. The black arrows show the polygonal tubule-like structures formed by HPC. The values are the mean ± SE of ﬁve measurements of branching
points in randomly selected image areas in three separate experiments. ⁄Signiﬁcant difference compared with EBM-2 alone (p < 0.05). §Signiﬁcant difference compared with
EBM-2 + GF (p < 0.05). Magniﬁcation 4 and 20. (ii) An elongated BV-like structure formed by HPC cultured for 15 h in EBM-2 + TRAP. Magniﬁcation 20. Note the apparent
complex polygonal structure formed by HPC cultured in the presence of TRAP.
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100 lg ml1 did not further increase the overall number of capil-
laries (2.0-fold increase compared with the control CAM;
p < 0.05), and the tissue near the ﬁlter disk did not exhibit the
extensive sprouted capillaries observed in the presence of 25 and
50 lg ml1 TRAP, as noted above. These results thus indicate that
25–50 lg ml1 TRAP is the optimal concentration for the strong
stimulation of BV formation in this ex vivo model.
4. Discussion
The process of neovascularization, fundamental in both devel-
opment and the repair/regeneration of adult tissue [1,10,16], in-
volves vasculogenic differentiation of stem cells into endothelial
precursors [1,10,16] and angiogenic formation of an organized net-
work of BV-like tubular structures by endothelial precursors
[1,12,10]. It has previously been shown that HPC cells cultured in
medium that facilitates vasculogenesis are able to form endothe-
lial-like cells [3,4], and the results of the present study suggest that
EMD and a low-molecular-weight fraction of EMD (Fraction C)
strongly stimulated the HPC vasculogenic differentiation of the
HPC cells, in contrast to the high-molecular-weight EMD Fraction
A, which suppressed this process. Moreover, the present study also
showed for the ﬁrst time that the main component of Fraction C, a
TRAP derived by N-terminal proteolytic clipping of the full-length
amelogenin appeared to enhance HPC cell vasculogenesis, based on
up-regulation of expression of the endothelial markers VEGFR2,
Tie-1, Tie-2, VE-cadherin and vWF by the HPC cells. The apparent
marked stimulation of vasculogenic differentiation of HPC cells
by the TRAP peptide was found to be comparable to the effects
of known GF (VEGF and EGF) on vasculogenic differentiation of hu-
man umbilical cord blood-derived mesenchymal stem cells and the
murine embryonic mesenchymal cell line C3H/10T/1/2, in which
the expression of VE-cadherin, vWF, Tie-1 and Tie-2 is also up-reg-
ulated [36,37].
The present study has also shown that HPC cells cultured in vas-
culogenic conditions in the presence of TRAP were able to internal-
ize markedly higher levels of acetylated LDL, indicating that TRAP
induced the expression of ‘‘scavenger’’ receptors, a key functional
characteristic of EC. Notably, the proportions of HPC cells that were
able to internalize acetylated LDL after incubation with EBM-2
alone and with EBM-2 + TRAP were found to be signiﬁcantly higher
than the HPC cell subpopulation that expressed VE-cadherin and
vWF after incubation in these same two media. The reason for this
is not yet known, thus further investigations are required to get
clariﬁcation on this discrepancy.
Under selective vasculogenesis-inducing conditions, the present
study showed that TRAP stimulated HPC cell expression of the
early endothelial marker gene VEGFR2 (a tyrosine kinase receptor
for the VEGF ligand), the late genes Tie-1 and Tie-2 (tyrosine kinase
receptors for angiopoietin that is expressed exclusively by EC [58])
and the late gene VE-cadherin (an endothelial cell adhesion mole-
cule). Notably, the early endothelial gene VEGFR1 was found to be
unaffected by the TRAP peptide, similar to that previously reported
in HPC cells when cultured under non-selective growth conditions
in the presence of EMD [59]. Although the reason for the lack of
VEGFR1 transcript up-regulation by TRAP is not yet understood,
this receptor has previously been identiﬁed as a ‘‘src’’ oncogene
involved in abnormal cell proliferation and development of a neo-
plastic phenotype [60,61], knockdown of this gene resulting in loss
of unlimited population doubling and ability to form tumors [62].
Thus, while these data indicate that the VEGFR1 receptor may be of
functional importance in neoplastic cells [62], it is unlikely to be
involved in the normal cellular physiology of the non-transformed
HPC used here.
Previous studies have suggested that both non-fractionated
(non-heat-treated) EMP and heat-treated EMD stimulated the che-
motactic migration of HUVEC and HMVEC in vitro [18,19,22,29], a
process which, together with the formation of tubular-like
structures, is a fundamental feature of angiogenic differentiation
Fig. 7. Effects of increasing concentrations of TRAP on angiogenesis ex vivo. BV development after 3 days of treatment of chick embryo CAM ex vivo with TRAP (1–
100 lg ml1). Embryos treated with bovine serum albumin were used as a control. The black arrows show vascular bundle-like ‘‘allantoic capillaries’’ (C). Magniﬁcation 1.5.
The numbers show the relative capillary density (number of total capillaries in a micrograph) in the presence of TRAP compared with the control CAM. The values are the
mean ± SE of measurements of six separate experiments. ⁄Signiﬁcant difference compared with the control (bovine serum albumin), deﬁned as 1.0 (p < 0.05). The higher
magniﬁcation (magniﬁcation 2.5) image of the CAM treated with 25 lg ml1 shows an artery (AR) from which allantoic capillaries have sprouted. Note the apparently
increased number of capillaries when the CAM was treated with 50 lg ml1TRAP.
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[34,63]. In contrast, other studies have reported the lack of effect of
EMD on HUVEC and HMVEC chemotaxis [18,22], the discrepancies
arising possibly because of the use of different preparations of EMP
and EMD containing different proportions of the constituent pro-
teins, including the TRAP peptide, and also the presence of GF
(e.g., TGF b and PDGF) in the non-heat-treated preparation
[19,29]. In the present study, chemically synthesized TRAP was
shown to markedly stimulate the chemotactic migration of both
HPC and HUVEC, suggesting that the presence of this peptide in
EMD is likely to have been at least partly responsible for the pro-
chemotactic activity of the cells. Moreover, the present results also
provided strong evidence that the TRAP peptide promoted the
formation of branched structures characteristic of angiogenic
differentiation. Although a recent study using a non-heat-treated
preparation of EMP reported that neither a high- (>15 kDa) nor
low-molecular-weight (<6 kDa) fraction of EMP was able to in-
crease the formation of angiogenic-associated tubular structures
by HMVEC [19], both of these fractions were found to be cross-con-
taminated with both high- and low-molecular-weight components
[19]. In contrast, the data presented here using the chemically pre-
pared TRAP show the ability of this peptide to induce HPC to form
signiﬁcantly greater numbers of complex polygonal tubule-like
structures than found in control cultures (in the absence of TRAP),
indicating that this synthetic peptide is able to stimulate angiogen-
esis in vitro.
The pro-angiogenic activity of TRAP was further established
using an ex vivo chick embryo CAM model, which demonstrated
that the presence of this peptide increased the number of allantoic
vessels compared with control eggs treated with bovine serum
albumin. A previous study using a murine angiogenesis model also
showed that a low-molecular-weight fraction of heat-treated EMD
(<6 kDa), presumably containing the TRAP peptide, exhibited
strong angiogenic activity in vivo [30]. However, in this study the
high-molecular-weight fraction (<15 kDa) was found to have sim-
ilar activity in vivo, although the speciﬁc active component(s) of
these fractions were not identiﬁed and both the fractions were
found to contain components of differing molecular sizes (as noted
above) that may have had differential effects on angiogenesis, un-
like the synthetic TRAP peptide used here.
The identiﬁcation of a small peptide with potent neovasculo-
genic activity, as described here, may be an important additional
tool in the repertoire of therapies for periodontal wound healing.
Thus this peptide, and possibly smaller synthetic sequences de-
rived therefrom, might constitute a consistent, reproducible and
far less costly means to treat a common and widespread disorder
with a far more predictable clinical outcome. Further, our ﬁndings
highlight the future potential of a possibly new class of therapeutic
drug for promoting early stages in the repair and regeneration of
many types of tissue that are dependent on the formation of new
BV, possibly even including TRAP-mediated neovasculogenesis in
patients suffering from atherosclerosis.
5. Conclusions
The results of this study demonstrate that the low-molecular-
weight Fraction C obtained from EMD promotes vasculogenic dif-
ferentiation in vitro. Further, the data presented here have also
shown, for the ﬁrst time, that the amelogenin-derived TRAP pep-
tide component of Fraction C is capable of stimulating vasculo-
genic and angiogenic differentiation in vitro and ex vivo. This
type of peptide, and chemically modiﬁed compounds derived
therefrom, might thereby represent a novel class of drug able to
elicit new blood vessel formation and promote wound healing
in vivo.
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